5-Amino-1MQ: What the Evidence Shows for Fat Loss and Body Composition

5-Amino-1MQ is one of those compounds that gets sold in the "peptide" space without actually being a peptide. It is a small molecule — specifically an inhibitor of an enzyme called nicotinamide N-methyltransferase (NNMT) — and it is marketed hard for fat loss, raising NAD⁺, boosting metabolism, and even building muscle. The pitch is seductive: a once-a-day oral capsule that tells your fat cells to burn more fuel. The problem is the same one that runs through this whole category, and we'll say it plainly before anything else.

The honest headline: 5-Amino-1MQ has a genuinely interesting mechanism and some striking results in animals — knocking down or inhibiting NNMT protected mice from diet-induced obesity — but there is essentially no human clinical trial evidence that it produces fat loss, NAD⁺ gains, or muscle in people. It is not a peptide in the strict sense (it's a small molecule), it is not FDA-approved for anything, and it is sold as a grey-market research chemical. Every impressive number you read about it comes from a mouse or a cell dish. Hold that frame against everything below.

What 5-Amino-1MQ Actually Is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective, membrane-permeable small-molecule inhibitor of NNMT — the enzyme nicotinamide N-methyltransferase². To understand why anyone cares about blocking it, you have to understand what NNMT does. NNMT consumes nicotinamide (a form of vitamin B3 your body can recycle into NAD⁺) and methylates it for disposal. When NNMT runs hot in fat tissue, the theory goes, it siphons off nicotinamide and burns through the cell's methyl-group supply — an altered metabolic state associated with obesity.

So the rationale is mechanistic and indirect: block NNMT, and you should preserve nicotinamide (supporting NAD⁺), free up methyl groups, and push fat cells toward a more energy-burning state. That is the entire scientific case for 5-Amino-1MQ as a fat-loss compound. It is a reasonable hypothesis — but it is a hypothesis built almost entirely on animal biology.

The Preclinical Case — Real, and Entirely in Animals

Here is where 5-Amino-1MQ earns its reputation, and the data deserve a fair hearing because they are genuinely the strongest part of the story.

The foundational finding came in 2014. Researchers showed that knocking down NNMT protected mice from diet-induced obesity¹. In that work, reducing NNMT expression in fat and liver increased cellular energy expenditure and protected the animals against high-fat-diet weight gain — direct evidence that NNMT is a real metabolic lever in rodents, not just an interesting enzyme. That paper, published in Nature, is the reason the whole NNMT-inhibitor field exists.

The next step was to ask whether a drug could do what genetic knockdown did. In 2018, a study reported that selective, membrane-permeable small-molecule NNMT inhibitors — the 5-amino-1MQ chemical class — reversed diet-induced obesity in mice². Obese animals given the inhibitor lost fat mass. This is the single most-cited justification sellers point to, and it is real. Later work refined the picture, showing that combining a reduced-calorie diet with NNMT inhibition established a distinct metabolic state in mice — suggesting the compound's effects interact with diet rather than replacing it³.

Read together, this is a coherent and legitimately promising body of preclinical work. If mouse studies decided the question, 5-Amino-1MQ would be a strong fat-loss candidate worth taking seriously.

What Is Missing: Humans

Notice the species line running through every result above: mouse, mouse, mouse. That is not a nitpick — it is the entire problem.

There is no published, controlled human clinical trial showing that 5-Amino-1MQ causes fat loss, raises NAD⁺, improves body composition, or builds muscle in people. The marketing language — "clinically shown to support fat loss," "boosts NAD⁺," "preserves lean mass" — borrows the confidence of the mouse data and presents it as if it had already been demonstrated in humans. It has not. A small molecule that reverses obesity in mice is a compelling reason to run a human trial. It is not evidence that the human trial would succeed.

This matters because mouse-to-human translation in metabolism is notoriously unreliable. The history of metabolic drugs is littered with compounds that melted fat off mice and did nothing — or caused harm — in people. We see the same pattern across the category: in our review of MOTS-c, striking rodent endurance data has never been confirmed by a single human performance trial. The "it worked in mice" evidence tier is exactly where 5-Amino-1MQ sits, and that tier is not proof.

The NAD⁺ and Muscle Claims

Two secondary claims deserve a direct word, because they show up constantly in marketing.

The NAD⁺ claim is mechanistically plausible — inhibiting NNMT should spare nicotinamide and support NAD⁺ levels — but plausible is not measured. There is no human data demonstrating that taking 5-Amino-1MQ meaningfully raises NAD⁺ in people, let alone that any such change produces a benefit you would feel. The leap from "this enzyme touches NAD⁺ metabolism" to "this capsule will raise your NAD⁺ and make you healthier" is exactly the kind of pathway-to-payoff jump that collapses under scrutiny.

The muscle claim is even thinner. NNMT also plays roles in skeletal muscle and stem-cell biology, which sellers stretch into "preserves and builds muscle." There is no human trial — and no clean animal performance trial — supporting 5-Amino-1MQ as a muscle-building agent. Treat it as marketing extrapolation, not a finding. If your actual goal is body composition, our honest guide to peptides for fat loss walks through how often these mechanistic stories fail to deliver in controlled human studies.

The Regulatory and Quality Reality

Even setting the evidence gap aside, the way 5-Amino-1MQ reaches consumers should give anyone pause.

It is not FDA-approved. 5-Amino-1MQ is not an approved drug for any indication, and it has not gone through the clinical-trial process that approval requires. Practically everything sold to consumers is an unapproved grey-market "research chemical," typically labeled "not for human consumption" or "for research use only." That label is not a formality — it means no regulator is checking the identity, dose, or purity of what is in the capsule or vial.

That sourcing problem is a real, independent safety concern layered on top of the missing efficacy data. When you buy an unregulated research chemical, you cannot verify that the product contains what the label claims, at the dose claimed, free of contaminants. We lay out the legality and quality framework in detail in our guide to where to buy peptides and the research-chemical legality maze, and it applies fully here. For the practical questions people ask about how the compound is taken, our 5-Amino-1MQ dosage page covers what's circulated in the community — while being clear that those protocols are not backed by human trials either.

Bottom Line

5-Amino-1MQ rests on a genuinely interesting idea: NNMT is a real metabolic enzyme, knocking it down protected mice from diet-induced obesity, and a small-molecule inhibitor in this class reversed obesity in obese mice. That preclinical work is legitimate and is the honest core of the compound's appeal.

What is missing is the only thing that would justify taking it for fat loss: even one controlled human trial showing 5-Amino-1MQ produces fat loss, raises NAD⁺, or improves body composition in people. Right now there is none. Add that it isn't actually a peptide, isn't FDA-approved for anything, and is sold as an unverified grey-market research chemical, and the verdict is straightforward — 5-Amino-1MQ is a promising research molecule and a reasonable trial candidate, not a proven human fat-loss compound. Treat any confident "it melted fat off me" claim as unproven anecdote until human trials exist. For where this and the rest of the field rank on real evidence, and the research tools and calculators we use to keep the claims honest, start there before you start anywhere else.